At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 30 enrolled
Drug / intervention
daptomycindrug
Likely dose
daptomycin 8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·interventional·Posted Jun 19, 2008·Updated Aug 29, 2016
In Brief
A Phase 3 clinical trial evaluating daptomycin for Late Effects of Surgery and 2 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This investigation is a prospective, open-label pharmacokinetic study of daptomycin prophylaxis in patients undergoing coronary artery bypass graft surgery without valvular replacement.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartJul 2008
Primary CompletionOct 2010
TodayJul 2026
First PostedJun 19, 2008
Enrollment StartJul 1, 2008
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.0 years ago
Interventions
daptomycindrug
Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9% normal saline (NS) and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.